20:50:06 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriLäkemedel & Handel
NattoPharma är ett norskt bolag verksamma inom utveckling av läkemedel. Idag innehas störst fokus på utveckling av diverse kosttillskott. Ledande varumärken säljs huvudsakligen via MenaQ7, ett vitamintillskott av K2 karaktär. En stor del av verksamheten fokuserar på forskning och utveckling inom arbetsområdet, vilket sker via separata dotterbolag. Bolaget etablerades 2004 och har sitt huvudkontor i Oslo.

Kalender

2022-01-26 Bokslutskommuniké 2021
2021-07-14 Kvartalsrapport 2021-Q2
2021-06-30 Årsstämma 2021
2021-05-27 Ordinarie utdelning NATTO 0.00 NOK
2021-02-17 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-07-15 Kvartalsrapport 2020-Q2
2020-06-22 Ordinarie utdelning NATTO 0.00 NOK
2020-06-19 Årsstämma 2020
2020-05-06 Kvartalsrapport 2020-Q1
2020-02-19 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning NATTO 0.00 NOK
2019-05-29 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-02-13 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NATTO 0.00 NOK
2018-05-30 Årsstämma 2018
2018-02-08 Bokslutskommuniké 2017
2017-11-24 Extra Bolagsstämma 2017
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-16 Ordinarie utdelning NATTO 0.00 NOK
2017-05-15 Årsstämma 2017
2017-05-15 Kapitalmarknadsdag 2017
2017-05-15 Kvartalsrapport 2017-Q1
2017-02-08 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-20 Kvartalsrapport 2016-Q1
2016-05-20 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2014-11-26 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-05-27 Kvartalsrapport 2014-Q1
2014-02-17 Bokslutskommuniké 2013
2013-11-26 Kvartalsrapport 2013-Q3
2013-08-27 Kvartalsrapport 2013-Q2
2013-05-22 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-11-15 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-16 Kvartalsrapport 2012-Q1
2012-02-28 Bokslutskommuniké 2011
2012-02-13 Extra Bolagsstämma 2012
2011-11-17 Kvartalsrapport 2011-Q3
2011-10-31 Extra Bolagsstämma 2011
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-19 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010
2021-03-01 09:05:39
Chairman of the board of NattoPharma ASA ("NattoPharma") and primary insider,
Frode Marc Bohan, and his related parties, including TG Montogomery AS ("TGM"),
have earlier irrevocably pre-accepted, if made and completed, the voluntarily
offer (the "Offer") that Compagnie des Levures Lesaffre ("Lesaffre") is due to
launch with an offer period that will commence on or prior to 19 March 2021,
cf. the press release dated 15 February 2021 regarding the Offer and NattoPharma
ASA's stock exchange notice dated 25 February 2021 regarding amendments to the
Offer.

Today Frode Marc Bohan's related party TGM has agreed to purchase 330 360 shares
(the "Additional Shares") in NattoPharma at a price of NOK 38 per share, subject
to the Offer being completed. TGM's pre-acceptance of the Offer covers any
shares TGM owned the date TGM gave its irrevocable pre-acceptance to Lesaffre
and any shares that TGM may acquire in NattoPharma prior to the completion of
the Offer. This means that TGM upon completion of the acquisition of the
Additional Shares thereafter will transfer the Additional Shares to Lesaffre for
the offer price, which currently is NOK 35.

Following the completion of the acquisition of the Additional Shares, TGM will
hold 2 065 482 shares in NattoPharma, representing 10,41% of the
total registered share capital and voting rights in NattoPharma, while primary
insider Frode Bohan together with TGM and other related parties will control 3
976 789 shares in NattoPharma representing 20,04% of the total registered share
capital and voting rights in NattoPharma, excluding 100 000 options NattoPharma
that Frode Bohan has agreed to exercise and transfer to Lesaffre under the
Offer.

TGM is also a related party to Kim Øien who is deputy board member in
NattoPharma and consequently a primary insider. Following the completion of the
acquisition of the Additional Shares Kim Øien together with TGM and other
related parties will control 2 265 482 shares in NattoPharma representing 11,42%
of the total registered share capital and voting rights in NattoPharma.